We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

215 hedge funds and large institutions have $783M invested in Vir Biotechnology in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 72 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $2.65M | Put options by funds: $1.92M

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

3% more funds holding

Funds holding: 209 → 215 (+6)

4% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 72

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.15% less ownership

Funds ownership: 65.83% → 64.67% (-1.2%)

13% less capital invested

Capital invested by funds: $901M → $783M (-$118M)

Holders
215
Holders Change
+6
Holders Change %
+2.87%
% of All Funds
3.11%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
34
Increased
75
Reduced
72
Closed
25
Calls
$2.65M
Puts
$1.92M
Net Calls
+$732K
Net Calls Change
+$390K

Top Buyers

1
O
OrbiMed
New York
+$16.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$7.6M
3
Millennium Management
Millennium Management
New York
+$5.82M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
+$5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.54M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$25.5M
2
State Street
State Street
Massachusetts
-$18.9M
3
Citigroup
Citigroup
New York
-$9.97M
4
BCM
Bridgeway Capital Management
Texas
-$4.6M
5
Barclays
Barclays
United Kingdom
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHK
126
Point72 Hong Kong
Hong Kong
$174K +$121K +12,598 +181%
AIM
127
Aigen Investment Management
New York
$171K +$184K +19,224 New
PAS
128
Point72 Asia (Singapore)
Singapore
$169K +$151K +15,755 +492%
COPPSERS
129
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$167K +$1.65K +172 +0.9%
DTL
130
Dynamic Technology Lab
Singapore
$160K -$63.5K -6,619 -27%
Simplex Trading
131
Simplex Trading
Illinois
$159K +$127K +13,221 +279%
Point72 Asset Management
132
Point72 Asset Management
Connecticut
$157K -$143K -14,900 -46%
VA
133
Vident Advisory
Georgia
$155K +$51.7K +5,391 +45%
Ohio Public Employees Retirement System (OPERS)
134
Ohio Public Employees Retirement System (OPERS)
Ohio
$151K -$6.01K -627 -4%
CUAMC
135
China Universal Asset Management Company
China
$142K -$95.8K -9,988 -38%
BC
136
Bridgefront Capital
Texas
$140K +$151K +15,751 New
SFI
137
Susquehanna Fundamental Investments
Pennsylvania
$135K +$146K +15,200 New
AQR Capital Management
138
AQR Capital Management
Connecticut
$134K -$106K -11,022 -42%
Bank of Montreal
139
Bank of Montreal
Ontario, Canada
$132K -$62.9K -6,561 -31%
TCM
140
Teza Capital Management
Illinois
$132K -$21.1K -2,195 -13%
MOACM
141
Mutual of America Capital Management
New York
$127K -$4.98K -519 -3%
Los Angeles Capital Management
142
Los Angeles Capital Management
California
$119K +$128K +13,331 New
Capstone Investment Advisors
143
Capstone Investment Advisors
New York
$118K +$128K +13,306 New
A
144
AlphaQuest
New York
$113K +$71.5K +7,452 +142%
Amundi
145
Amundi
France
$113K -$23.1K -2,413 -16%
GCM
146
Graham Capital Management
Connecticut
$112K +$121K +12,594 New
ET
147
Entropy Technologies
New York
$112K +$121K +12,573 New
BP
148
Ballentine Partners
Massachusetts
$111K -$11.4K -1,185 -9%
NAM
149
NorthCrest Asset Manangement
Minnesota
$104K – – –
SWM
150
Salvus Wealth Management
New Jersey
$104K – – –
4 5
6
7 8

VIR Hedge Fund Activity: Q2 2024 in Review

215 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2024, worth a combined $783M — down 13% from $901M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new VIR positions and 25 closed out — a net gain of 9 holders — while 75 added to existing stakes and 72 trimmed.

The largest buyer was OrbiMed, adding an estimated $16.1M. The largest seller was Citadel Advisors, cutting an estimated $25.5M.

  • 215 institutional investors held Vir Biotechnology (VIR) as of Q2 2024, up from 209 in Q1 2024.
  • Funds reported $783M of Vir Biotechnology stock for Q2 2024, down 13% quarter-over-quarter.
  • 34 funds opened new Vir Biotechnology positions in Q2 2024 and 25 closed out, a net change of +9 holders.
  • The largest Vir Biotechnology buyer in Q2 2024 was OrbiMed, an estimated $16.1M added.
  • The largest Vir Biotechnology seller in Q2 2024 was Citadel Advisors, an estimated $25.5M sold.

Based on aggregated 13F filings for Q2 2024.